Motility News

CHICAGO — Magnetic sphincter augmentation using the Linx device was more effective than proton pump inhibitor therapy for treating regurgitation in patients with GERD, according to interim data from the Caliber trial presented at Digestive Disease Week.

The FDA has granted 510(k) clearance to the endoscopic diagnostics company Crospon for its new Endoflip system with Flip Topography Module, which provides a new way to evaluate motility disorders during endoscopy.

CHICAGO — Data from a study of patients with diabetic gastroparesis showed that relamorelin reduced symptoms; however, data also showed the placebo effect was also strong, according to a presentation at Digestive Disease Week.

CHICAGO — Increased acid exposure time on reflux testing before lung transplantation predicts decline in pulmonary function after transplantation, according to research presented at Digestive Disease Week.

CHICAGO — Trajectory analysis of wireless pH monitoring can help guide diagnosis and management of patients with GERD who do not respond to PPIs and have variable esophageal acid exposure over time, according to research presented at Digestive Disease Week.

The national nonprofit Esophageal Cancer Action Network filed a citizen petition asking the FDA to require new labels on over-the-counter reflux drugs warning about the risk for esophageal cancer associated with persistent reflux or GERD.

According to a review published in Pediatric Annals, literature provides insight that cyproheptadine, a serotonin antagonist, is potentially effective and safe for the treatment of functional gastrointestinal disorders.

RedHill Biopharma Ltd. has signed an exclusive license agreement with Entera Health Inc. granting them the U.S. rights to EnteraGam, a commercially-available medical food intended to manage chronic diarrhea and loose stools, according to a press release.

In the AGA’s newly released clinical practice update on long-term use of proton pump inhibitors, experts recommended that health care providers should weigh the risks and benefits of these medications before prescribing them to patients. They further emphasized that the benefits likely outweigh the risks when PPIs are prescribed appropriately.

Prometheus Laboratories has announced the launch of a new test called IBcause that simultaneously evaluates 20 stool and serum measures to help diagnose many common causes of persistent diarrhea.